Drug safety updates, recalls and regulatory warnings from MHRA, organised for rapid clinical review and specialty follow-up.
Amiodarone carries serious risks of pulmonary, hepatic, and thyroid toxicity requiring regular patient monitoring and supervision throughout treatment Healthcare professionals must ensure appropriate baseline investigations and regular follow-up assessments to detect potentially life-threatening adverse…
20 May 2026 · Read clinical summaryAmiodarone carries serious risks of pulmonary, hepatic, and thyroid toxicity requiring regular patient monitoring and supervision throughout treatment Healthcare professionals must ensure appropriate baseline investigations and regular follow-up…
Amiodarone has been associated with serious and potentially life-threatening side effects, particularly of the lung, liver, and thyroid gland. We remind healthcare professionals that patients should be supervised…
The MHRA has identified suicidal thoughts and behaviours as a safety concern with finasteride and dutasteride, requiring additional risk minimisation measures in clinical practice. Psychiatric adverse effects and…
Nasal decongestant sprays/drops containing xylometazoline or oxymetazoline carry a risk of rebound congestion and rhinitis medicamentosa with overuse, requiring cautious patient counselling on duration of use. Tachyphylaxis (reduced…
A falsified version of Mounjaro (tirzepatide) KwikPen 15mg solution for injection has been found supplied through one online pharmacy in the UK. The falsified product is labelled with…
The Commission on Human Medicines (CHM) has temporarily restricted use of the IXCHIQ Chikungunya vaccine in people aged 65 years and over following very rare fatal reactions reported…
IXCHIQ Chikungunya vaccine: updates to restrictions of use following safety revi...
Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ische...
GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warni...
The Commission on Human Medicines (CHM) has endorsed changes to the risk minimisation measures for isotretinoin, following a review of the impact of the measures implemented in 2023.…
The MHRA has reviewed the warnings regarding addiction, dependence, withdrawal, and tolerance for gabapentin, pregabalin, benzodiazepines, and z-drugs. The findings (detailed in the Public Assessment Report) were that…
Rybelsus ® (semaglutide tablets): transition to new formulation and risk of med...